1
|
Andrews SL, Ghaderi-Najafabadi M, Gong P, Shamkhi N, Carleton L, Schofield C, Kessler T, Samani NJ, Webb TR, Morris GE. SVEP1 influences monocyte to macrophage differentiation via integrin α4β1/α9β1 and Rho/Rac signalling. Biochim Biophys Acta Mol Cell Res 2023; 1870:119479. [PMID: 37100352 DOI: 10.1016/j.bbamcr.2023.119479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 03/09/2023] [Accepted: 04/15/2023] [Indexed: 04/28/2023]
Abstract
BACKGROUND The large extracellular matrix protein SVEP1 mediates cell adhesion via integrin α9β1. Recent studies have identified an association between a missense variant in SVEP1 and increased risk of coronary artery disease (CAD) in humans and in mice Svep1 deficiency alters the development of atherosclerotic plaques. However how SVEP1 functionally contributes to CAD pathogenesis is not fully understood. Monocyte recruitment and differentiation to macrophages is a key step in the development of atherosclerosis. Here, we investigated the requirement for SVEP1 in this process. METHODS SVEP1 expression was measured during monocyte-macrophage differentiation in primary monocytes and THP-1 human monocytic cells. SVEP1 knockout THP-1 cell lines and the dual integrin α4β1/α9β1 inhibitor, BOP, were utilised to investigate the effect of these proteins in THP-1 cell adhesion, migration and cell spreading assays. Subsequent activation of downstream integrin signalling intermediaries was quantified by western blotting. RESULTS SVEP1 gene expression increases in monocyte to macrophage differentiation in human primary monocytes and THP-1 cells. Using two SVEP1 knockout THP-1 cells we observed reduction in monocyte adhesion, migration, and cell spreading compared to control cells. Similar results were found with integrin α4β1/α9β1 inhibition. We demonstrate reduced activity of Rho and Rac1 in SVEP1 knockout THP-1 cells. CONCLUSIONS SVEP1 regulates monocyte recruitment and differentiation phenotypes through an integrin α4β1/α9β1 dependent mechanism. GENERAL SIGNIFICANCE These results describe a novel role for SVEP1 in monocyte behaviour relevant to CAD pathophysiology.
Collapse
Affiliation(s)
- S L Andrews
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - M Ghaderi-Najafabadi
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - P Gong
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - N Shamkhi
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - L Carleton
- Horizon Discovery Ltd., 8100 Cambridge Research Park, Cambridge CB25 9TL, United Kingdom.
| | - C Schofield
- Horizon Discovery Ltd., 8100 Cambridge Research Park, Cambridge CB25 9TL, United Kingdom.
| | - T Kessler
- Department of Cardiology, German Heart Centre Munich, Technical University of Munich, Munich, Germany.; German Centre of Cardiovascular Research (DZHK e. V.), Partner Site Munich Heart Alliance, Munich, Germany.
| | - N J Samani
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - T R Webb
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| | - G E Morris
- Department of Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester LE3 9QP, United Kingdom.
| |
Collapse
|
2
|
Lahu S, Presch A, Ndrepepa G, Bernlochner I, Joner M, Xhepa E, Kufner S, Sager HB, Mayer K, Kessler T, Laugwitz KL, Schunkert H, Neumann FJ, Kastrati A, Cassese S. Ticagrelor or prasugrel in patients with acute coronary syndrome and high bleeding risk. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The relative efficacy and safety of more potent P2Y12 inhibitors in patients with acute coronary syndrome (ACS) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) remains unclear.
Purpose
To study the treatment effect of ticagrelor and prasugrel in PCI patients presenting with ACS and HBR.
Methods
This post-hoc analysis of the ISAR-REACT 5 trial included patients with ACS undergoing PCI, randomized to ticagrelor or prasugrel, in whom HBR was defined as per Academic Research Consortium criteria. The primary (efficacy) endpoint was the composite of all-cause death, myocardial infarction, or stroke. The secondary (safety) endpoint was Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding. Outcomes were assessed 12 months after randomisation.
Results
Out of the 3,239 patients included in this analysis, 486 fulfilled the criteria for ARC-HBR definition (HBR group; ticagrelor, n=230 and prasugrel, n=256), whilst 2,753 did not (non-HBR group; ticagrelor, n=1,375 and prasugrel, n=1,378). Compared to the non-HBR group, the HBR group had a higher risk for the primary (hazard ratio [HR]=3.57, 95% confidence interval [CI], 2.79–4.57, p<0.001), and secondary endpoint (HR=2.94 [2.17–3.99], p<0.001). In the HBR group, the primary (HR=1.09; [0.73–1.62]) and secondary (HR=1.18 [0.67–2.08]) endpoints were not statistically different between patients assigned to ticagrelor and prasugrel. In the non-HBR group, the primary endpoint (HR=1.62 [1.19–2.20]) occurred more frequently in patients assigned to ticagrelor as compared to patients assigned to prasugrel, without difference in safety (HR=1.08 [0.74–1.58]). There was no treatment allocation-by-HBR status interaction with respect to the primary (p for interaction = 0.123), or secondary (p for interaction = 0.803) endpoints.
Conclusions
In patients with ACS undergoing PCI, HBR status increased both ischemic and bleeding risks without significant impact on the relative efficacy or safety of ticagrelor versus prasugrel. These results warrant confirmation in larger cohorts.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): German Center for Cardiovascular Research (DZHK)Deutsches Herzzentrum München
Collapse
Affiliation(s)
- S Lahu
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - A Presch
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - G Ndrepepa
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - I Bernlochner
- Klinikum rechts der Isar, Medizinische Klinik und Poliklinik Innere Medizin I , Munich , Germany
| | - M Joner
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - E Xhepa
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - S Kufner
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - H B Sager
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - K Mayer
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - T Kessler
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - K L Laugwitz
- Klinikum rechts der Isar, Medizinische Klinik und Poliklinik Innere Medizin I , Munich , Germany
| | - H Schunkert
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - F J Neumann
- University Heart Center Freiburg-Bad Krozingen, Department of Cardiology and Angiology II , Bad Krozingen , Germany
| | - A Kastrati
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| | - S Cassese
- German Heart Center Munich, Technical University of Munich , Munich , Germany
| |
Collapse
|
3
|
Hoffmann DC, Hai L, Wagener R, Mandelbaum H, Xie R, Hausmann D, Dominguez Azorín D, Weil S, Sievers P, Cebulla G, Ito J, Warnken U, Venkataramani V, Ernst K, Reibold D, Will R, Suvà ML, Herold-Mende C, Sahm F, Winkler F, Schlesner M, Wick W, Kessler T. JS08.6.A A connectivity signature for glioblastoma. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Tumor cell extensions called tumor microtubes (TMs) in glioma resemble neurites during neurodevelopment and connect glioma cells to a network that has considerable relevance for tumor progression and therapy resistance. The determination of interconnectivity in individual tumors has been challenging and the impact of tumor cell connectivity on patient survival remained unresolved so far.
Material and Methods
A connectivity signature was derived by single-cell RNA-sequencing (scRNA-Seq) of highly and lowly connected cells obtained from an SR101 dye transfer xenograft model of primary glioblastoma (GB). The signature was validated in different in vitro models of cell-to-cell connectivity and could be translated to GB clinical specimens.
Results
34 of 40 connectivity genes were related to neurogenesis, neural tube development or glioma progression, including the TM-network-relevant GAP43 gene. Astrocytic-like and mesenchymal-like GB cells had the highest connectivity signature scores in scRNA-Seq data of patient-derived xenografts and patient samples. In 230 human GBs, high connectivity correlated with the mesenchymal expression subtype, TP53 wildtype, and with dismal patient survival. CHI3L1 was identified and validated as a robust molecular marker of connectivity with a functional relevance.
Conclusion
The connectivity signature gives novel insights into brain tumor biology, provides a proof-of-principle that tumor cell connectivity is relevant for patients’ prognosis, and serves as a robust biomarker that can be used for future clinical trials
Collapse
Affiliation(s)
- D C Hoffmann
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
- Faculty of Biosciences, Heidelberg University , Heidelberg , Germany
| | - L Hai
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
- Bioinformatics and Omics Data Analytics, DKFZ , Heidelberg , Germany
| | - R Wagener
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
| | - H Mandelbaum
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - R Xie
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - D Hausmann
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - D Dominguez Azorín
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - S Weil
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
| | - P Sievers
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg , Heidelberg , Germany
- Clinical Cooperation Unit Neuropathology, DKTK, DKFZ , Heidelberg , Germany
| | - G Cebulla
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - J Ito
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - U Warnken
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - V Venkataramani
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
- Department of Neuroanatomy, Institute for Anatomy and Cell Biology, Heidelberg University , Heidelberg , Germany
| | - K Ernst
- Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ) , Heidelberg , Germany
- Division of Pediatric Neurooncology, DKTK, DKFZ , Heidelberg , Germany
| | - D Reibold
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| | - R Will
- Genomics and Proteomics Core Facility, DKTK, DKFZ , Heidelberg , Germany
| | - M L Suvà
- Broad Institute of Harvard and MIT, Cambridge, MA, United States; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School , Boston, MA , United States
| | - C Herold-Mende
- Department of Neurosurgery, Heidelberg University Hospital , Heidelberg , Germany
| | - F Sahm
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg , Heidelberg , Germany
- Clinical Cooperation Unit Neuropathology, DKTK, DKFZ , Heidelberg , Germany
| | - F Winkler
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
| | - M Schlesner
- Bioinformatics and Omics Data Analytics, DKFZ , Heidelberg , Germany
- Biomedical Informatics, Data Mining and Data Analytics, Faculty of Applied Computer Science and Medical Faculty, University of Augsburg , Augsburg , Germany
| | - W Wick
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
| | - T Kessler
- Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
- Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg , Germany
| |
Collapse
|
4
|
Leyvraz S, Schütte M, Kessler T, Lamping M, Burock S, Ochsenreither S, Amstislavskiy V, Risch T, Jelas I, Ulrich C, Dobos G, Klauschen F, Schäfer R, Lange B, Klinghammer K, Yaspo ML, Keilholz U. 847P Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Ahlburg J, Gjørup F, Kessler T, Smith R, Henry P, Christensen M. Novel in situ powder neutron diffraction setups – the creation of a modern magnetic compound. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322092026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
6
|
Wick A, Sander A, Koch M, Bendszus M, Combs S, Haut T, Dormann A, Walter S, Pertz M, Merkle-Lock J, Selkrig N, Limprecht R, Baumann L, Kieser M, Sahm F, Schlegel U, Winkler F, Platten M, Wick W, Kessler T. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. BMC Cancer 2022; 22:645. [PMID: 35692047 PMCID: PMC9190129 DOI: 10.1186/s12885-022-09720-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 05/30/2022] [Indexed: 12/05/2022] Open
Abstract
Background Given the young age of patients with CNS WHO grade 2 and 3 oligodendrogliomas and the relevant risk of neurocognitive, functional, and quality-of-life impairment with the current aggressive standard of care treatment, chemoradiation with PCV, of the tumour located in the brain optimizing care is the major challenge. Methods NOA-18 aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG) (n = 182 patients per group accrued over 4 years) thereby delaying radiotherapy and adding the chemoradiotherapy concept at progression after initial radiation-free chemotherapy, allowing for effective salvage treatment and delaying potentially deleterious side effects. QOS represents a new concept and is defined as OS without functional and/or cognitive and/or quality of life deterioration regardless of whether tumour progression or toxicity is the main cause. The primary objective is to show superiority of an initial CETEG treatment followed by partial brain radiotherapy (RT) plus PCV (RT-PCV) at progression over partial brain radiotherapy (RT) followed by procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV) and best investigators choice (BIC) at progression for sustained qOS. An event concerning a sustained qOS is then defined as a functional and/or cognitive and/or quality of life deterioration after completion of primary therapy on two consecutive study visits with an interval of 3 months, tolerating a deviation of at most 1 month. Assessments are done with a 3-monthly MRI, assessment of the NANO scale, HRQoL, and KPS, and annual cognitive testing. Secondary objectives are evaluation and comparison of the two groups regarding secondary endpoints (short-term qOS, PFS, OS, complete and partial response rate). The trial is planned to be conducted at a minimum of 18 NOA study sites in Germany. Discussion qOS represents a new concept. The present NOA trial aims at showing the superiority of CETEG plus RT-PCV over RT-PCV plus BIC as determined at the level of OS without sustained functional deterioration for all patients with oligodendroglioma diagnosed according to the most recent WHO classification. Trial registration Clinicaltrials.govNCT05331521. EudraCT 2018–005027-16.
Collapse
Affiliation(s)
- A Wick
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - A Sander
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - M Koch
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - M Bendszus
- Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
| | - S Combs
- Department of Radiation Oncology at the Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
| | - T Haut
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - A Dormann
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - S Walter
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - M Pertz
- Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany
| | - J Merkle-Lock
- Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany
| | - N Selkrig
- Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany
| | - R Limprecht
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - L Baumann
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - M Kieser
- Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany
| | - F Sahm
- Department of Neuropathology, University Hospital Heidelberg, DKTK and CCU Neuropathology, DKFZ, Heidelberg, Germany
| | - U Schlegel
- Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany
| | - F Winkler
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - M Platten
- DKTK, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKFZ, Heidelberg, Germany.,Department of Neurology, Medical faculty, MCTN, University of Heidelberg, Mannheim, Germany
| | - W Wick
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany. .,German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .,Neurology Clinic, University of Heidelberg & CCU Neurooncology, DKFZ, Im Neuenheimer Feld 400, D-69120, Heidelberg, Germany.
| | - T Kessler
- Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.,German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
7
|
Alhalabi O, Göttmann M, Gold M, Fletcher M, Hielscher T, Iskar M, Kessler T, Wittmann E, Schlue S, Rahman S, Hai L, Hansen-Palmus L, Puccio L, Nakano I, Herold-Mende C, Baumgartner U, Day B, Wick W, Sahm F, Fraenkel E, Phillips E, Goidts V. P04.04 Optimizing dasatinib for glioblastoma treatment. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma is the most common primary malignancy of the central nervous system with a dismal prognosis, even with surgical and chemoradiotherapy. Expression profiling studies classify IDH-wildtype Glioblastoma into three subtypes: Proneural (PN), mesenchymal (MES) and classical (CL). A promising target to inhibit in Glioblastoma is the non-receptor tyrosine kinase and proto-oncogene SRC. After robust pre-clinical results, SRC inhibitors like dasatinib did not improve survival of Glioblastoma patients after recurrence in clinical trials.
MATERIAL AND METHODS
Consolidating efforts to personalize cancer therapy, we use in silico analyses backed by in vitro and in vivo experiments on Glioblastoma stem-like cells (GSCs) derived from primary patient tumors to present a novel stratification strategy for dasatinib therapy in glioblastoma. To further tackle dasatinib resistance in GSCs, a pooled shRNA library against 5000 genes was combined with dasatinib to identify genes whose knockdown sensitizes GSCs to dasatinib. This was integrated with proteomics and phosphoproteomics data of dasatinib inhibited GSCs.
RESULTS
We found MES tumors with high expression of SERPINH1 to be sensitive to dasatinib inhibition, compared to the CL and PN subtypes. Interestingly, SRC phosphorylation status did not predict the efficacy of dasatinib inhibition. Computational analyses integrating data from the loss-of-function dropout viability screen and proteomics/phosphoproteomics using a novel modification of the SamNet algorithm identified Wee1, a tyrosine kinase involved in cell-cycle signaling, as a potential combination inhibition target with dasatinib. Further validation experiments showed a robust synergistic effect through combination of dasatinib and the wee1 inhibitor, MK-1775 in PN GSCs.
CONCLUSION
This study highlights strategies to optimize dasatinib treatment in different glioblastoma subtypes. While the stratification of patients harboring mesenchymal glioblastoma with SERPINH1 overexpression could provide an option in this particular subtype, combining dasatinib or other SRC inhibitors with Wee1 inhibitors could present an additional possibility for treating resistant proneural tumors
Collapse
Affiliation(s)
- O Alhalabi
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - M Göttmann
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - M Gold
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, United States
| | - M Fletcher
- Division of Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer Research Center, Heidelberg, Germany
| | - T Hielscher
- Division of Biostatistics (C060), German Cancer Research Center, Heidelberg, Germany
| | - M Iskar
- Division of Molecular Genetics, Heidelberg Center for Personalized Oncology, German Cancer Research Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany, Heidelberg, Germany
| | - T Kessler
- Department of Neurology and Neurooncology Program; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - E Wittmann
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Schlue
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - S Rahman
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - L Hai
- Junior Research Group Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany, Heidelberg, Germany
| | - L Hansen-Palmus
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - L Puccio
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - I Nakano
- Department of Neurosurgery, University of Alabama, Birmingham, AL, United States
| | - C Herold-Mende
- 8Department of Neurosurgery, Division of Experimental Neurosurgery, Heidelberg University Hospital, 69120 Heidelberg, Germany, Heidelberg, Germany
| | - U Baumgartner
- Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, Australia
- School of Biomedical Sciences, The University of Queensland, Brisbane, Australia
| | - B Day
- Cell and Molecular Biology Department, QIMR Berghofer Medical Research Institute, Sid Faithfull Brain Cancer Laboratory, Brisbane, Australia
- School of Biomedical Sciences, The University of Queensland, Brisbane, Australia
| | - W Wick
- Department of Neurology and Neurooncology Program; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
- Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - F Sahm
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - E Fraenkel
- Eli and Edythe Broad Institute of MIT and Harvard, Cambridge, MA, United States
- Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, United States
| | - E Phillips
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - V Goidts
- Brain Tumor Translational Targets, DKFZ Junior Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
8
|
Kessler T, Pink D, Reichardt P, Palmerini E, Stacchiotti S, Grignani G, Rutkowski P, Hemmerle T, Neri D, Schliemann C. 1554TiP A randomized phase II study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced or metastatic soft tissue sarcoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
9
|
Kollmer J, Kessler T, Sam G, Hayes JM, Lentz SI, Heiland S, Bendszus M, Wick W, Weiler M. Magnetization transfer ratio: a quantitative imaging biomarker for 5q spinal muscular atrophy. Eur J Neurol 2020; 28:331-340. [PMID: 32918834 DOI: 10.1111/ene.14528] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 09/02/2020] [Indexed: 12/22/2022]
Abstract
BACKGROUND AND PURPOSE We quantified peripheral nerve lesions in adults with 5q-linked spinal muscular atrophy (SMA) type 3 by analysing the magnetization transfer ratio (MTR) of the sciatic nerve, and tested its potential as a novel biomarker for macromolecular changes. METHODS Eighteen adults with SMA 3 (50% SMA 3a, 50% SMA 3b) and 18 age-/sex-matched healthy controls prospectively underwent magnetization transfer contrast imaging in a 3-Tesla magnetic resonance scanner. Two axial three-dimensional gradient echo sequences, with and without an off-resonance saturation rapid frequency pulse, were performed at the right distal thigh. Sciatic nerve regions of interest were manually traced on 10 consecutive axial slices in the images generated without off-resonance saturation, and then transferred to corresponding slices generated by the sequence with the off-resonance saturation pulse. Subsequently, MTR and cross-sectional areas (CSAs) of the sciatic nerve were analysed. In addition, detailed neurologic, physiotherapeutic and electrophysiologic examinations were conducted in all patients. RESULTS Sciatic nerve MTR and CSA reliably differentiated between healthy controls and SMA 3, 3a or 3b. MTR was lower in the SMA 3 (P < 0.0001), SMA 3a (P < 0.0001) and SMA 3b groups (P = 0.0020) than in respective controls. In patients with SMA 3, MTR correlated with all clinical scores, and arm nerve compound motor action potentials (CMAPs). CSA was lower in the SMA 3 (P < 0.0001), SMA 3a (P < 0.0001) and SMA 3b groups (P = 0.0006) than in controls, but did not correlate with clinical scores or electrophysiologic results. CONCLUSIONS Magnetization transfer ratio is a novel imaging marker that quantifies macromolecular nerve changes in SMA 3, and positively correlates with clinical scores and CMAPs.
Collapse
Affiliation(s)
- J Kollmer
- Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany
| | - T Kessler
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - G Sam
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - J M Hayes
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA
| | - S I Lentz
- Department of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI, USA
| | - S Heiland
- Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.,Division of Experimental Radiology, Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany
| | - M Bendszus
- Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany
| | - W Wick
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - M Weiler
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| |
Collapse
|
10
|
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier A, Angenendt L, Berdel A, Kessler T, Wilms C, Hartmann W, Wardelmann E, Kraehling T, Heindel W, Gerss J, Schmidt H, Lenz G, Mesters R, Berdel W. 563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Kessler T. Targets to watch in ischemic heart disease. DRUG FUTURE 2020. [DOI: 10.1358/dof.2020.45.7.3107704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Berberich A, Bartels F, Tang Z, Pusch S, Hucke N, Kessler T, Dong Z, Wiestler B, Winkler F, Platten M, Wick W, Abdollahi A, Lemke D. P11.07 LAPTM5 functions as a tumor suppressor via CD40 - NFêB pathway inhibition and represents a potential biomarker for temozolomide sensitivity in CD40 proficient glioblastoma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Glioma therapy is challenged by the invasive nature of glioma resulting in tumor recurrence and treatment resistance. Lysosomal protein transmembrane 5 (LAPTM5) was identified to inhibit invasion by screening for invasion-associated genes in glioma. The aim of this study was to decipher the function of LAPTM5 in glioblastoma and its interaction with the CD40 receptor which was shown to be highly expressed in up to 40% of glioblastoma.
METHODS
LAPTM5 expression was correlated with clinical outcome of glioma patients. Knockdown of LAPTM5 was performed in different glioma cell lines to analyze the impact on clonogenicity, invasiveness, sensitivity to temozolomide chemotherapy and tumorigenicity in-vitro and in-vivo in a subcutaneous xenograft mouse model. Expression array was used to elucidate the underlying pathways. CD40 knockdown and overexpression was induced to prove the crosstalk of LAPTM5 and CD40.
RESULTS
LAPTM5 expression correlated with better overall survival in high grade glioma patients and acted as a tumor suppressor in CD40 positive glioblastoma cells. LAPTM5 inhibited CD40-mediated NFκB activation resulting in anti-invasive, anti-clonogenic and temozolomide sensitizing effects in-vitro and in-vivo. Vice-versa, knockdown of LAPTM5 enhanced tumorigenicity by activation of the NFκB pathway which was overcome by NFκB inhibition. Importantly, CD40 expression was required for LAPTM5-mediated tumor suppressive activity.
CONCLUSION
LAPTM5 conveyed tumor suppressive and temozolomide sensitizing effects in CD40-positive glioblastoma by inhibition of CD40-mediated NFκB activation and thereby might provide a reasonable biomarker for sensitivity to temozolomide in CD40-positive glioblastoma.
Collapse
Affiliation(s)
- A Berberich
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| | - F Bartels
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| | - Z Tang
- German Cancer Research Center, Heidelberg, Germany
- Division of Molecular& Translational Radiation Oncology, University Hospital, Heidelberg, Germany
| | - S Pusch
- German Cancer Research Center, Heidelberg, Germany
| | - N Hucke
- German Cancer Research Center, Heidelberg, Germany
| | - T Kessler
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| | - Z Dong
- Tongji Hospital, Department of Neurosurgery, Wuhan, China
| | - B Wiestler
- Department of Neuroradiology, Klinikum rechts der Isar der Technischen Universität, München, Germany
| | - F Winkler
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| | - M Platten
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, Mannheim, Germany
| | - W Wick
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| | - A Abdollahi
- German Cancer Research Center, Heidelberg, Germany
- Division of Molecular& Translational Radiation Oncology, University Hospital, Heidelberg, Germany
| | - D Lemke
- German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, University Hospital, Heidelberg, Germany
| |
Collapse
|
13
|
Lambrecht L, Wobst J, Wolf B, Schunkert H, Kessler T. Platelet Inhibition In Carriers Of The Gucy1A3 Coronary Artery Disease Risk Allele. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Hentschel L, Richter S, Kopp HG, Kasper B, Kunitz A, Grünwald V, Kessler T, Chemnitz JM, Pelzer U, Schuler U, Freitag J, Schilling A, Hornemann B, Arndt K, Ehninger G, Bornhäuser M, Schuler M. Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Friedrich M, Bunse L, Bunse T, Green E, Kessler T, Pusch S, Sanghvi K, Carretero R, Gutcher I, von Deimling A, Wick W, Platten M. P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Friedrich
- German Cancer Research Center, Heidelberg, Germany
| | - L Bunse
- German Cancer Research Center, Heidelberg, Germany
| | - T Bunse
- German Cancer Research Center, Heidelberg, Germany
| | - E Green
- German Cancer Research Center, Heidelberg, Germany
| | - T Kessler
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - S Pusch
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - K Sanghvi
- German Cancer Research Center, Heidelberg, Germany
| | - R Carretero
- German Cancer Research Center, Heidelberg, Germany
| | - I Gutcher
- Bayer Pharmaceuticals, Berlin, Germany
| | - A von Deimling
- Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany
| | - W Wick
- Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany
| | - M Platten
- Department of Neurology, University Hospital Mannheim, Heidelberg, Germany
| |
Collapse
|
16
|
Xie R, Kessler T, Grosch J, Huang L, Solecki G, Wick W, Winkler F. OS3.5 Dynamic insights into the cellular heterogeneity of malignant gliomas. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- R Xie
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - T Kessler
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - J Grosch
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - L Huang
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - G Solecki
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - W Wick
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| | - F Winkler
- Clinical Cooperation Unit Neurooncology, Heidelberg, Germany
| |
Collapse
|
17
|
Latzer P, Kessler T, Sahm F, Rübmann P, Hielscher T, Platten M. P04.30 Methadone does not increase toxicity of temozolomide in glioblastoma cells. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.264] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- P Latzer
- Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany
- Klinische Kooperationseinheit Neuroonkologie, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | - T Kessler
- Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany
- Klinische Kooperationseinheit Neuroonkologie, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | - F Sahm
- Universitätsklinikum Heidelberg, Abteilung für Neuropathologie, Heidelberg, Germany
- Klinische Kooperationseinheit Neuropathologie, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | - P Rübmann
- Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany
- Klinische Kooperationseinheit Neuroonkologie, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | - T Hielscher
- Deutsches Krebsforschungszentrum (DKFZ), Abteilung Biostatistik, Heidelberg, Germany
| | - M Platten
- Universitätsklinik Mannheim, Neurologische Klinik, Mannheim, Germany
- Neuroimmunologie und Hirntumorimmunologie, Deutsches Krebsforschungszentrum (DFKZ), Heidelberg, Germany
| |
Collapse
|
18
|
Lindner C, Piel C, Kessler T. Gemeinsamkeit erleben – Wertschätzung erfahren – Teilhabe durch Gruppenaktivitäten für ältere Menschen. Das Gesundheitswesen 2018. [DOI: 10.1055/s-0038-1667802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Lindner
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| | - C Piel
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| | - T Kessler
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| |
Collapse
|
19
|
Lindner C, Piel C, Kessler T. Gemeinsamkeit erleben – Wertschätzung erfahren. Psychother Psych Med 2018. [DOI: 10.1055/s-0038-1668034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- C Lindner
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| | - C Piel
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| | - T Kessler
- Friedrich-Schiller-Universität Jena, Institut für Psychologie, Lehrstuhl für Sozialpsychologie, Jena, Deutschland
| |
Collapse
|
20
|
Russo G, Cacciamani G, Cocci A, Kessler T, Morgia G, Serefoglu E, Verze P, Albersen M. 062 A systematic review and network meta-analysis on the clinical efficacy of intralesional therapy for Peyronie’s Disease in controlled clinical trials. J Sex Med 2018. [DOI: 10.1016/j.jsxm.2018.04.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Schwoeppe C, Hartmann W, Berdel W. CD13-targetierte vaskuläre Infarzierung als experimentelle Therapie beim kleinzelligen Lungenkarzinom. Pneumologie 2018. [DOI: 10.1055/s-0037-1619257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- LH Schmidt
- Schwerpunkt Pneumologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - J Stucke-Ring
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - C Brand
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - C Schliemann
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - S Harrach
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - T Muley
- University Hospital Heidelberg; Thoraxklinik; Translational Research Unit
| | - E Herpel
- Pathologisches Institut der Universität Heidelberg; Gewebebank des NCT Heidelberg
| | - T Kessler
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - M Mohr
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - D Görlich
- Institut für Statistik und Biometrie, Universitätsklinikum Münster
| | - M Kreuter
- Pneumologie und Beatmungsmedizin, Thoraxklinik am Universitätsklinikum Heidelberg; Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL)
| | - G Lenz
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - E Wardelmann
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - M Thomas
- Department of Thoracic Oncology, Thoraxklinik Heidelberg, University Hospital Heidelberg
| | - C Schwoeppe
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| | - W Hartmann
- Gerhard Domagk Institut für Pathologie, Universitätsklinikum Münster
| | - W Berdel
- Hämatologie und Onkologie, Medizinische Klinik A, Universitätsklinikum Münster
| |
Collapse
|
22
|
Turnbull D, Bucht S, Davies A, Haberberger D, Kessler T, Shaw JL, Froula DH. Raman Amplification with a Flying Focus. Phys Rev Lett 2018; 120:024801. [PMID: 29376697 DOI: 10.1103/physrevlett.120.024801] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Indexed: 06/07/2023]
Abstract
We propose a new laser amplifier scheme utilizing stimulated Raman scattering in plasma in conjunction with a "flying focus"-a chromatic focusing system combined with a chirped pump beam that provides spatiotemporal control over the pump's focal spot. Pump intensity isosurfaces are made to propagate at v=-c so as to be in sync with the injected counterpropagating seed pulse. By setting the pump intensity in the interaction region to be just above the ionization threshold of the background gas, an ionization wave is produced that travels at a fixed distance ahead of the seed. Simulations show that this will make it possible to optimize the plasma temperature and mitigate many of the issues that are known to have impacted previous Raman amplification experiments, in particular, the growth of precursors.
Collapse
Affiliation(s)
- D Turnbull
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
| | - S Bucht
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
- University of Rochester Department of Physics and Astronomy, Bausch and Lomb Hall, Rochester, New York 14627, USA
| | - A Davies
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
- University of Rochester Department of Physics and Astronomy, Bausch and Lomb Hall, Rochester, New York 14627, USA
| | - D Haberberger
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
| | - T Kessler
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
| | - J L Shaw
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
| | - D H Froula
- University of Rochester Laboratory for Laser Energetics, 250 East River Road, Rochester, New York 14623, USA
- University of Rochester Department of Physics and Astronomy, Bausch and Lomb Hall, Rochester, New York 14627, USA
| |
Collapse
|
23
|
Leyvraz S, Schuette M, Rieke D, Kessler T, Ochsenreither S, Amstislavskiy V, Risch T, Wierling C, Joehrens K, Peuker C, Lamping M, Burock S, Poch G, Kiecker F, Schaefer R, Lange B, Lehrach H, Joussen A, Keilholz U, Yaspo ML. Precision medicine for the treatment of metastatic uveal melanoma: A pilot study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Kessler T, Wobst J, Wolf B, Eckhold J, Vilne B, Hollstein R, Sager H, Aherrahrou R, Kastrati A, Bjoerkegren J, Erdmann J, Lusis A, Civelek M, Kaiser F, Schunkert H. P4471The 4q32.1 coronary artery disease locus influences disease risk via differential transcription factor binding. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Trenkwalder T, Kessler T, Schunkert H. [Genetic testing in polygenic diseases : Atrial fibrillation, arterial hypertension and coronary artery disease]. Herz 2017; 42:440-448. [PMID: 28536780 DOI: 10.1007/s00059-017-4576-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Genetic testing plays an increasing role in cardiovascular medicine. Advances in technology and the development of novel and more affordable (high throughput) methods have led to the identification of genetic risk factors in research and clinical practice. Also, this progress has simplified the screening of patients and individuals at risk. In case of rare monogenic diseases, diagnostics, risk stratification, and, in some cases, treatment decisions have become easier. For common, polygenic cardiovascular diseases, the situation is more complex due to interaction of modifiable external risk factors and nonmodifiable factors like genetic predisposition. Over the last few years, it has been shown that multiple genes are involved in the pathophysiology of these cardiovascular diseases rather than one single gene. In the following article, we give an overview of the genetic risk factors in polygenic cardiovascular diseases as atrial fibrillation, arterial hypertension and coronary artery disease. Furthermore, we aim to illustrate in which cases genetic testing is recommended in these diseases.
Collapse
Affiliation(s)
- T Trenkwalder
- Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität München, Lazarettstr. 36, 80636, München, Deutschland
| | - T Kessler
- Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität München, Lazarettstr. 36, 80636, München, Deutschland.
| | - H Schunkert
- Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität München, Lazarettstr. 36, 80636, München, Deutschland
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) e. V., Munich Heart Alliance, München, Deutschland
| |
Collapse
|
26
|
Kessler T, Sahm F, Sadik A, Hertenstein A, Bendszus M, von Deimling A, Platten M, Wick W. OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Hertenstein A, Chiblak S, Hielscher T, Ciprut S, Lemke D, Thomé C, Kessler T, Abdollahi A, Platten M, Wick W. P08.19 Resistance towards the MDM2 inhibitor idasanutlin is mediated via the NFkB pathway and IGFBP1 upregulation in glioblastoma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Thomé C, Blaes J, Rübmann P, Hertenstein A, Kessler T, Sonner J, Deumelandt K, Breckwoldt M, Platten M, Wick W. P01.32 NDRG1 induced downregulation of CCL2 influences the migration of macrophages and impacts the tumor microenvironement. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Kessler T, Mohr M, Görlich D, Marra A, Müller-Tidow C, Wiewrodt R, Berdel W, Schwoeppe C, Hartmann W. Die Bedeutung einer Expression von CD13 im nicht-kleinzelligen Lungenkarzinom. Pneumologie 2017. [DOI: 10.1055/s-0037-1598275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- LH Schmidt
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - J Stucke-Ring
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - C Brand
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - C Schliemann
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - T Kessler
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - M Mohr
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - D Görlich
- Institut für Statistik und Biometrie, Universitätsklinikum Münster
| | - A Marra
- Thoraxchirurgie, Klinikum Bremen Ost
| | - C Müller-Tidow
- Universitätsklinik und Poliklinik für Innere Medizin IV, Halle (Saale)
| | - R Wiewrodt
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - W Berdel
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - C Schwoeppe
- Medizinische Klinik A, Schwerpunkt Pneumologie, Universitätsklinikum Münster
| | - W Hartmann
- Institut für Pathologie, Universitätsklinikum Münster
| |
Collapse
|
30
|
Fröhlich F, Shadrin A, Kessler T, Wierling C, Heinig M, Theis F, Lange B, Lehrach H, Hasenauer J. Large-scale modeling of cancer signaling: Mechanistic modeling meets Big Data. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32716-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Brænne I, Willenborg C, Reiz B, Zeng L, Tragante do Ó V, Meitinger T, Samani N, Kessler T, Asselbergs F, Erdmann J, Schunkert H. Pleiotropic molecular targets of coxibs reveals novel genomic loci conferring coronary artery disease risk. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Abt D, Hechelhammer L, Müllhaupt G, Kessler T, Schmid HP, Engeler D, Mordasini L. 1080 Prostatic artery embolization vs conventional TUR-P in the treatment of benign prostatic hyperplasia: First results of a prospective, randomized non-inferiority trial. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/s1569-9056(16)61081-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Kessler T, Kaess B, Bourier F, Erdmann J, Schunkert H. [Genetic analyses as basis for a personalized medicine in patients with coronary artery disease]. Herz 2014; 39:186-93. [PMID: 24464254 DOI: 10.1007/s00059-013-4048-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Knowledge about the etiology of coronary artery disease (CAD) entered new dimensions using genome-wide association studies. The current situation is that 46 chromosomal loci have been identified to be associated with CAD with genome-wide significance, i.e. p<5×10(-8), in Western Europeans. As the individual DNA sequence remains unchanged after fertilization, the risk variants cannot occur due to confounders, such as secondary disease processes. Thus, it can be proposed that these variants are directly affecting a primary and thereby causal pathophysiological process in CAD. Interestingly, only 20% of the effects mediated by the identified loci can be explained by the influence of traditional risk factors. This implies that yet unknown mechanisms and, as a consequence, new therapeutic targets play an important role in the pathophysiology of CAD. However, the high allele frequency of risk loci was also surprising. In the diploid chromosome set Western European individuals carry on average 30-50 risk variants at the 46 loci. Considering this, every individual in the population carries a larger or smaller genetic predisposition for CAD. On the other hand it is remarkable that many risk allele carriers seem to be able to compensate the genetic risk: even in old age not everyone suffers from CAD. This indicates yet unknown gene-gene and gene-environment interactions and limits the current possibilities in individual risk prediction.
Collapse
Affiliation(s)
- T Kessler
- Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität München, Lazarettstr. 36, 80636, München, Deutschland
| | | | | | | | | |
Collapse
|
34
|
Ramaty E, Maor E, Peltz-Sinvani N, Brom A, Grinfeld A, Kivity S, Segev S, Sidi Y, Kessler T, Sela BA, Segal G. Low ALT blood levels predict long-term all-cause mortality among adults. A historical prospective cohort study. Eur J Intern Med 2014; 25:919-21. [PMID: 25468741 DOI: 10.1016/j.ejim.2014.10.019] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2014] [Revised: 10/11/2014] [Accepted: 10/24/2014] [Indexed: 12/14/2022]
Abstract
BACKGROUND Increased blood levels of alanine amino transferase (ALT, also known as SGPT; serum glutamic pyruvic transaminase) serve as a marker of liver injury by various mechanisms. Less is known about the clinical implications associated with low-normal ALT levels. Previous studies showed low ALT levels to be associated with poor long-term outcomes among elderlies, serving as a biomarker for increased incidence of frailty and subsequent risk of mortality. However, it has not been determined yet whether low-normal ALT values might be predictive of frailty and mortality in younger, middle-aged adults. METHODS We conducted a historical prospective cohort analysis. RESULTS A total of 23,506 adults with ALT levels within the normal range, at the mean age of 48 ± 11 years, participating in an annual screening program for preventive medicine, were followed-up for a median period of 8.5 years during which 638 died. Low-normal ALT values (serum ALT activity <17IU/L) were found to be predictive for increased risk of all-cause mortality (HR=1.6; 95% CI 1.34-1.92; p<0.001). Statistically significant correlation was demonstrated even after applying a multifactorial model correction for age, gender, eGFR, low albumin, arterial hypertension, diabetes mellitus and ischemic heart disease. CONCLUSIONS We suggest that low-normal ALT values may serve as an independent predictive marker for increased long-term mortality in middle-aged adults.
Collapse
Affiliation(s)
- E Ramaty
- Department of Internal Medicine "T", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel.
| | - E Maor
- Leviev Heart Institute, Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel; The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - N Peltz-Sinvani
- Department of Internal Medicine "T", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - A Brom
- Department of Internal Medicine "T", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | | | - S Kivity
- Internal Medicine "C", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel; The Zabludovicz Center for Autoimmune Diseases, Israel; The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - S Segev
- Institute of Preventive Medicine, Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - Y Sidi
- Internal Medicine "C", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - T Kessler
- Department of Internal Medicine "T", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - B A Sela
- Institute of Chemical Pathology, Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| | - G Segal
- Department of Internal Medicine "T", Chaim Sheba Medical Center,(2) Tel Hashomer, Ramat Gan, Israel
| |
Collapse
|
35
|
Abstract
The individual genetic susceptibility is a cornerstone in the pathogenesis of coronary artery disease (CAD). The search for the genetic background and the subsequently altered molecular mechanisms has been ineffective for several years. The increase in genome-wide association studies in recent years has changed the scenario and more than 40 variants have so far been identified to be highly significantly associated with CAD and the risk of myocardial infarction (MI). Whereas most of these findings affect frequent polymorphisms, exome-wide sequencing in families with a high prevalence of CAD revealed mutations with a high penetrance and as a consequence a high risk of suffering from MI. The findings allow a deeper insight into functional mechanisms involved in the pathogenesis of atherosclerosis. Furthermore, the data enables validation of the numerous epidemiologically identified risk markers with respect to the causal role in the development of CAD, making the genetic architecture of CAD much more transparent. Nevertheless, individual risk prediction has only made weak progress in the face of the new findings. Every individual without exception carries numerous risk alleles even when the number and effect strength shows individual differences. Thus, a varying degree of genetic susceptibility is shared by all of us. Current research is therefore focusing on the functional integration of genetic information to discover new approaches to prevention and therapy.
Collapse
Affiliation(s)
- T Kessler
- Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Lazarettstr. 36, 80636, München, Deutschland
| | | | | |
Collapse
|
36
|
Weiler M, Kessler T, Sahm F, Blaes J, Osswald M, Milford D, Urban S, Ruiz de Almodovar C, Heiland S, Wick W. O6.10 * GLIOMA CELL VEGFR-2 EXPRESSION IMPAIRS CHEMOTHERAPEUTIC AND ANTIANGIOGENIC TREATMENTS IN PTEN-DEFICIENT GLIOBLASTOMA. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.51] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Roiss M, Schiffmann J, Tennstedt P, Kessler T, Blanc I, Goetz A, Schlomm T, Graefen M, Reuter DA. Oncological long-term outcome of 4772 patients with prostate cancer undergoing radical prostatectomy: does the anaesthetic technique matter? Eur J Surg Oncol 2014; 40:1686-92. [PMID: 24613743 DOI: 10.1016/j.ejso.2014.02.223] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Revised: 01/31/2014] [Accepted: 02/07/2014] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Recent data suggest that using additional neuroaxial anaesthesia during oncological surgery is associated with favourable recurrence-free survival, when compared with general anaesthesia alone. We assessed the impact of adjunctive perioperative spinal anaesthesia and dose of opioids on the oncological long-term outcome of patients following radical prostatectomy. METHODS We selected patients from our institutional review board-approved database who consecutively underwent radical prostatectomy between 2002 and 2007. Patients were stratified by type of anaesthesia, administered as general anaesthesia alone, or spinal anaesthesia in addition to general anaesthesia. Biochemical recurrence-free survival, metastasis-free survival and overall survival were analysed by a multivariate Cox regression model and by Kaplan-Meier analysis in propensity-score based matched cohorts, adjusted for standard clinico-pathological variables and year of surgery. RESULTS Overall, 4772 patients were analysed. Regarding the type of anaesthesia no significant difference for biochemical recurrence-free survival, metastasis-free survival and overall survival was analysed by a multivariate Cox regression model (p = 0.5, 0.8 and 0.7). The Kaplan-Meier analyses after propensity-score matched based comparisons revealed no significant difference depending on type of anaesthesia for biochemical recurrence-free survival, metastasis-free survival and overall survival (p = 0.6, 0.1 and 0.4). The same accounted for a propensity-score matched model adjusted for the year of surgery on biochemical recurrence-free survival (p = 0.7). CONCLUSIONS The oncological outcome after radical prostatectomy was not affected by the adjunctive use of spinal anaesthesia.
Collapse
Affiliation(s)
- M Roiss
- Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany
| | - J Schiffmann
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
| | - P Tennstedt
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
| | - T Kessler
- Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany
| | - I Blanc
- Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany
| | - A Goetz
- Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany
| | - T Schlomm
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany; Department of Urology, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Germany
| | - M Graefen
- Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
| | - D A Reuter
- Department of Anaesthesiology, Center of Anaesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Germany.
| |
Collapse
|
38
|
Kessler T, Thiele K, Solano M, Arck P, Tiegs G, Erhardt A. Acetaminophen application during murine pregnancy triggers metabolic and immunological changes in dams and impairs fetal development. J Reprod Immunol 2012. [DOI: 10.1016/j.jri.2012.03.272] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Ahyai S, Kluth L, Chun F, Engel O, Reiss P, Jessel D, Isbarn H, Kessler T, Schreiter F, Fisch M, Dahlem R. MP-12.17 Extended Long-Term Results of Surgery for Urethral Stricture. Urology 2011. [DOI: 10.1016/j.urology.2011.07.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
40
|
Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol 2011; 23:990-6. [PMID: 21810729 DOI: 10.1093/annonc/mdr346] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in a median overall survival (OS) of ≤ 1 year. Elderly patients often present with cardiac comorbidity. Gemtuzumab ozogamicin (GO) is active in elderly (≥ 60 years) patients with relapsed AML with low cardiac toxicity. PATIENTS AND METHODS This randomized phase II study compared a standard combination of ara-C and daunorubicin (DNR; 7+3) versus ara-C plus gemtuzumab ozogamicin (7+GO) as the first course of induction therapy. Primary objectives were comparison of blast clearance on day 16, event-free survival (EFS), and remission duration. OS, complete remission (CR), and tolerability were secondary objectives. RESULTS One hundred and nineteen patients with de novo AML, treatment-related AML, AML with a history of myelodysplastic syndrome (MDS), or high-risk MDS entered the study. Median age of 115 patients (intent-to-treat population) was 69 years. Protocol outlined a second course 7+3 for patients without blast clearance and two courses of high-dose ara-C consolidation upon CR. Both treatments were equally effective in blast clearance, CR, EFS, remission duration, or OS (median: 7+3, 9 months; 7+GO, 10 months). Induction death rate was higher in the GO group due to veno-occlusive disease. CONCLUSION The study did not show significant superiority of 7+GO over standard 7+3.
Collapse
Affiliation(s)
- U Brunnberg
- Department of Medicine, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Mohr M, Hartig I, Kessler T, Hamisch C, Kliesch S, Krug U, Spieker T, Semik M, Wiebe K, Puehse G, Hertle L, Mueller-Tidow C, Mesters RM, Berdel WE. High-dose chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor- and intermediate-prognosis metastatic germ cell tumors: A retrospective monocenter analysis of 44 cases. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Algora A, Jordan D, Taín JL, Rubio B, Agramunt J, Perez-Cerdan AB, Molina F, Caballero L, Nácher E, Krasznahorkay A, Hunyadi MD, Gulyás J, Vitéz A, Csatlós M, Csige L, Aysto J, Penttilä H, Moore ID, Eronen T, Jokinen A, Nieminen A, Hakala J, Karvonen P, Kankainen A, Saastamoinen A, Rissanen J, Kessler T, Weber C, Ronkainen J, Rahaman S, Elomaa V, Rinta-Antila S, Hager U, Sonoda T, Burkard K, Hüller W, Batist L, Gelletly W, Nichols AL, Yoshida T, Sonzogni AA, Peräjärvi K. Reactor decay heat in 239Pu: solving the γ discrepancy in the 4-3000-s cooling period. Phys Rev Lett 2010; 105:202501. [PMID: 21231223 DOI: 10.1103/physrevlett.105.202501] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2010] [Indexed: 05/30/2023]
Abstract
The β feeding probability of (102,104,105,106,107)Tc, 105Mo, and 101Nb nuclei, which are important contributors to the decay heat in nuclear reactors, has been measured using the total absorption technique. We have coupled for the first time a total absorption spectrometer to a Penning trap in order to obtain sources of very high isobaric purity. Our results solve a significant part of a long-standing discrepancy in the γ component of the decay heat for 239Pu in the 4-3000 s range.
Collapse
Affiliation(s)
- A Algora
- IFIC (CSIC-Univ. Valencia), Valencia, Spain and Institute of Nuclear Research, Debrecen, Hungary
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Van Kerrebroeck P, Chartier-Kastler E, Castro-Diaz D, De Ridder D, Elneil S, Kaufmann A, Kessler T, Spinelli M, Wachter J, Stoevelaar H. UP-2.44: An electronic tool to support the selection of patients with overactive bladder syndrome for sacral neuromodulation. Urology 2010. [DOI: 10.1016/j.urology.2010.07.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Abstract
In analogy to solid neoplasms, accumulating data suggest the requirement of angiogenesis also for the development and progression of hematopoietic malignancies including acute myeloid leukemia (AML). Inhibition of increased microvessel density in bone marrow (BM) might be a promising target for pharmacological interventions aimed at reducing disease activity. Among the putative inhibitors of angiogenesis, thalidomide has demonstrated a considerable efficacy in myelodysplastic syndromes (MDS) and AML with overall response rates up to 56% and 25%, respectively. Responders experienced hematologic improvements with increased hemoglobin and platelet counts resulting in temporary transfusion independence. In AML, partial responses--defined as reduction of the leukemic blast cell infiltration of at least 50% in BM--occurred in four of 20 patients after one month of thalidomide administration in a previous phase I/II study. Additionally, we observed a long-term response in one AML patient of more than 20 months, meanwhile fulfilling the criteria of complete remission. The decrease in leukemic blast infiltration in BM of responders was accompanied by a significant reduction of the microvessel density. Overall adverse events caused by the drug consisted mainly of fatigue, constipation, skin rash and polyneuropathy with a tolerable dose of 200-400 mg p.o. per day. In conclusion, thalidomide as a single agent has significant anti-leukemic activity with some evidence for anti-angiogenic effects in BM, although the precise mechanism of action remains to be elucidated.
Collapse
Affiliation(s)
- M B Steins
- Department of Medicine/Hematology and Oncology, University of Muenster Albert-Schweitzer-Strasse 33, 48149 Muenster, Germany
| | | | | | | | | | | | | |
Collapse
|
45
|
Mohr M, Kessler T, Krug U, Hoffknecht P, Schmidt L, Wiebe K, Berdel W, Wiewrodt R. Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. Z Herz- Thorax- Gefäßchir 2010. [DOI: 10.1007/s00398-010-0766-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Liu Y, Beene JR, Havener CC, Vane CR, Geppert C, Gottwald T, Kessler T, Wies K, Wendt K. Time profile of ion pulses produced in a hot-cavity laser ion source. Rev Sci Instrum 2010; 81:02A505. [PMID: 20192360 DOI: 10.1063/1.3273071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The time spreads of Mn ions produced by three-photon resonant ionization in a hot-cavity laser ion source are measured. A one-dimensional ion-transport model is developed to simulate the observed ion time structures. Assuming ions are generated with a Maxwellian velocity distribution and are guided by an axial electric field, the predictions of the model agree reasonably well with the experimental data and suggest that the ions are radially confined in the ion source and a substantial fraction of the ions in the transport tube are extracted.
Collapse
Affiliation(s)
- Y Liu
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Jahn G, Hamprecht K, Kessler T, Beck R, Göhring K. PIX-8 Analysis of T-cell responses to adenovirus and human cytomegalovirus for the control of infection through adoptive T-cell transfer. J Clin Virol 2009. [DOI: 10.1016/s1386-6532(09)70213-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Sterr U, Legero T, Kessler T, Schnatz H, Grosche G, Terra O, Riehle F. Ultrastable lasers: new developments and applications. ACTA ACUST UNITED AC 2009. [DOI: 10.1117/12.825217] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
49
|
Liu Y, Baktash C, Beene JR, Geppert C, Gottwald T, Havener CC, Kessler T, Krause HF, Schultz DR, Stracener DW, Vane CR, Wies K, Wendt K. Emittance characterization of a hot-cavity laser ion source at Holifield Radioactive Ion Beam Facility. Rev Sci Instrum 2009; 80:083304. [PMID: 19725648 DOI: 10.1063/1.3184343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The first investigation of the transverse emittance of a hot-cavity laser ion source based on all-solid-state Ti:sapphire lasers is presented. The emittances of (63)Cu ion beams generated by three-photon resonant ionization are measured and compared with that of the (69)Ga and (39)K ion beams resulting from surface ionization in the same ion source. A self-consistent unbiased elliptical exclusion method is adapted for noise reduction and emittance analysis. Typical values of the rms and 90% fractional emittances of the Cu ion beams at 20 keV energy are found to be about 2 and 8 pi mm mrad, respectively, for the ion currents of 2-40 nA investigated. The emittances of the laser-produced Cu ion beams are smaller than those of the surface-ionized Ga and K ion beams.
Collapse
Affiliation(s)
- Y Liu
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Cheal B, Baczynska K, Billowes J, Campbell P, Charlwood FC, Eronen T, Forest DH, Jokinen A, Kessler T, Moore ID, Reponen M, Rothe S, Rüffer M, Saastamoinen A, Tungate G, Aystö J. Laser spectroscopy of niobium fission fragments: first use of optical pumping in an ion beam cooler buncher. Phys Rev Lett 2009; 102:222501. [PMID: 19658859 DOI: 10.1103/physrevlett.102.222501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2009] [Indexed: 05/28/2023]
Abstract
A new method of optical pumping in an ion beam cooler buncher has been developed to selectively enhance ionic metastable state populations. The technique permits the study of elements previously inaccessible to laser spectroscopy and has been applied here to the study of Nb. Model independent mean-square charge radii and nuclear moments have been studied for ;{90,90 m,91,91 m,92,93,99,101,103}Nb to cover the region of the N=50 shell closure and N approximately 60 sudden onset of deformation. The increase in mean-square charge radius is observed to be less than that for Y, with a substantial degree of beta softness observed before and after N=60.
Collapse
Affiliation(s)
- B Cheal
- Schuster Building, The University of Manchester, Brunswick Street, Manchester, M13 9PL, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|